Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPINION olaparib maintenance in platinum-sensitive relapsed non-germline BRCA-mutated ovarian cancer
NL-OMON48759Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of olaparib in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC), sponsored by AstraZeneca. Primary endpoint: Progression-free survival. Started Jun 2018; status: active, not recruiting.
02
Drugs
olaparib
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NL-OMON48759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48759.